Immix Biopharma gains on exclusive rights to blood cancer therapy

Immix Biopharma

14/12/2022 15:02

** Shares of cancer drug developer Immix Biopharma Inc
 IMMX.O  up 63% at $2.40
    ** Company says it has secured exclusive rights to blood
cancer therapy, NXC-201  urn:newsml:reuters.com:*:nGNX6KHwfw
    ** The decision was based on trial results in patients with
multiple myeloma, and in patients with AL Amyloidosis, a rare
disease that affects heart, kidneys and other organs, in two
separate published studies - Immix
    ** "Encouraged by the 100% complete response rate and 100%
organ response rate in AL Amyloidosis, we are planning to enroll
additional patients to validate these findings," says company
    ** Nearly 8.8 mln shares change hands, more than twice the
stock's 25-day avg
    ** Up to last close, stock down 59% YTD
 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))